TMEM92-AS1 has been shown to promote gastric cancer progression by targeting CCL5, and further study has shown that it may affect leukocytes via regulation of the expression of granulocyte colony-stimulating factor in gastric cancer tissues (Song et al., 2021). Here, CSF3 is linked to gastric cancer.